Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Pruritus, Atopic Dermatitis

In brief

This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to severe pruritus.

Key facts

Study ID
NCT04018027
Run by
Cara Therapeutics, Inc.
People needed
401
Starts
2019-06-29
Expected to finish
2021-04-01
Last updated by the study team
2022-04-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.